Radiopharmaceuticals Market by Product Type (Diagnostic Radiopharmaceuticals, Therapeutic Radiopharmaceuticals), by Isotope Type (Technetium-99m, Iodine-131, Lutetium-177, Gallium-68, Fluorine-18, Actinium-225, Yttrium-90, Radium-223), by Application (Oncology, Cardiology, Neurology, Thyroid Disorders, Others), by End User (Hospitals, Diagnostic Imaging Centers, Academic & Research Institutes, Cancer Treatment Centers), and by Region — Global Industry Perspective, Comprehensive Analysis, and Forecast 2026–2035
St. Catharines, Ontario, October 2026 — Vectomat Insights has published a new report titled ‘Radiopharmaceuticals Market by Product Type, Isotope Type, Application, End User, and Region — Global Industry Perspective, Comprehensive Analysis, and Forecast 2026–2035.’ The Global Radiopharmaceuticals market was valued at USD 9,248.6 Mn in 2025 and is projected to reach USD 25,884.6 Mn by 2035, growing at a CAGR of 10.84% during the forecast period 2026–2035, according to Vectomat Insights.
Diagnostic agents still earn 57.0% of 2025 revenue, but therapeutics are compounding twice as fast — Novartis' Pluvicto booked USD 1,994 Mn in 2025 sales and won a third U.S. label in July 2026 — while North America holds 40.3% of global revenue.
The Global Radiopharmaceuticals market was worth USD 9,248.6 Mn in 2025 and will reach USD 25,884.6 Mn by 2035 at a 10.84% CAGR, according to Vectomat Insights. North America leads with 40.3% of revenue. Diagnostic radiopharmaceuticals hold a 57.0% share, while Lutetium-177 and Actinium-225 therapeutics grow faster, and Asia Pacific is the fastest-growing region.
Key Insights Snapshot
| Metric | Value |
|---|---|
| Report Title | Global Radiopharmaceuticals Market Size, Share, Growth & Forecast By Product Type, Isotope Type, Application, and End User, 2026–2035 |
| Base Year Market Size | USD 9,248.6 Mn (2025) |
| Forecast Market Size | USD 25,884.6 Mn (2035) |
| CAGR | 10.84% |
| Forecast Period | 2026–2035 |
| Dominant Region | North America (40.3%) |
| Fastest-Growing Region | Asia Pacific |
| Dominant Segment | Diagnostic Radiopharmaceuticals (57.0%) |
| Dominant Application | Oncology |
| Report Format | |
| Publisher | Vectomat Insights |
What Pharmaceutical Leaders Need to Know About the Radiopharmaceuticals Market
Pharma R&D Heads: Pluvicto's 42% sales growth to USD 1,994 Mn in 2025 and its July 2026 hormone-sensitive label prove radioligand therapy can scale like a mainstream oncology franchise. Programs without an Actinium-225 or Lutetium-177 asset — and a secured isotope contract behind it — risk entering a USD 25.9 Bn category after the supply slots are gone.
Health-System CEOs: SNMMI expects dose demand to rise up to sixfold versus 2024 estimates, yet German centres already report roughly eight-week waits from progression to treatment. Systems that add shielded therapy rooms and nuclear medicine staff this budget cycle will capture referral volume that slower competitors lose.
Regulatory Affairs Directors: September 2026's approval of Curium's Bexlutry as the first copy of Lutathera opens a 505(b)(2) generic pathway for radioligands, while August 2026's CRL for ITM-11 shows manufacturing, not efficacy, is now where filings fail. Build CMC and third-party facility audits into the submission plan early.
Healthcare Investors: Two large deals in ten weeks — Curium's up-to-USD 8.0 Bn agreement for Lantheus and GE HealthCare's USD 945 Mn purchase of Sofie Biosciences — have reset valuation benchmarks. Isotope-supply and PET-manufacturing assets are the scarce inventory buyers now compete for.
Supply Chain & Procurement VPs: About 95% of global Mo-99 comes from six reactors, five of them over 50 years old, and the October 2024 Petten outage cut U.S. Tc-99m supply by up to 40%. Dual-sourcing generator contracts and locking multi-year Lutetium-177 offtake are cheaper now than during the next outage.
What Is the Radiopharmaceuticals Market?
The Radiopharmaceuticals Market refers to drugs that carry a radioactive isotope to image disease or to destroy it from inside the body. Why does it matter now? Because the therapy side has gone mainstream: Novartis' Pluvicto earned USD 1,994 Mn in 2025, and the FDA cleared it for hormone-sensitive prostate cancer in July 2026, moving radioligand therapy into earlier, larger patient pools. Diagnostics haven't stood still either — Technetium-99m still underpins roughly 80% of the 50 million-plus nuclear medicine procedures run each year. Vectomat Insights sizes the category at USD 9,248.6 Mn in 2025, rising to USD 25,884.6 Mn by 2035. The capital case has shifted from a specialty-imaging line item to an oncology growth platform.
How Is the Radiopharmaceuticals Market Segmented?
Diagnostic radiopharmaceuticals bring in 57.0% of 2025 revenue, or USD 5,272.5 Mn. That's the installed base talking: SPECT and PET scans run every day in thousands of hospitals. Therapeutic radiopharmaceuticals are where the momentum is, growing at a 15.3% two-year CAGR to USD 3,976.1 Mn as Lutetium-177 and Actinium-225 drugs win new labels. By isotope, Technetium-99m still leads at 33.7%, but Fluorine-18 grows fastest at 15.1%, helped by GE HealthCare's Flyrcado cardiac tracer and a wave of PSMA-PET agents. Oncology takes 46.8% of application revenue and hospitals 53.2% of end-user spend.
This report segments the Radiopharmaceuticals market as follows:
- By Product Type: Diagnostic Radiopharmaceuticals, Therapeutic Radiopharmaceuticals
- By Isotope Type: Technetium-99m, Iodine-131, Lutetium-177, Gallium-68, Fluorine-18, Actinium-225, Yttrium-90, Radium-223
- By Application: Oncology, Cardiology, Neurology, Thyroid Disorders, Others
- By End User: Hospitals, Diagnostic Imaging Centers, Academic & Research Institutes, Cancer Treatment Centers
- By Region: North America, Europe, Asia Pacific, Latin America, The Middle East, Africa
Which Region Leads the Radiopharmaceuticals Market?
North America owns 40.3% of the market, worth USD 3,727.2 Mn in 2025, and the U.S. alone reached USD 2,929.2 Mn. CMS's separate payment for pricier diagnostic agents and a delivery network that reaches nearly 600 Pluvicto treatment sites keep it ahead. Asia Pacific is the region to watch. It's the fastest-growing, as Japan approved Pluvicto in September 2025 and South Korea's market climbs at a 13.0% CAGR toward USD 953.5 Mn by 2035. Europe holds 25.9%, led by Germany at USD 680.8 Mn. Asia Pacific takes 22.7%, Latin America 4.9%, the Middle East 3.1% and Africa 3.1%.
Radiopharmaceuticals Market Growth Drivers
Radioligand Therapy Label Expansion — Pluvicto's sales jumped 42% to USD 1,994 Mn in 2025, and July 2026's hormone-sensitive approval pushes it into a far larger, earlier-stage patient pool.
PET Tracer Reimbursement and Launch Wave — Since January 2025, CMS has paid separately for diagnostic radiopharmaceuticals costing over USD 630 a day, and new PET agents like Gozellix and Flyrcado are filling that window.
Isotope and Manufacturing Capacity Build-Out — Bristol Myers Squibb is adding a USD 173 Mn second radiopharmaceutical plant in Indiana, and Cardinal Health has quadrupled weekly Actinium-225 output since late 2024.
Today's approval for an expanded indication for Pluvicto brings more choice to nearly three times as many patients.
(Source: Novartis media release, March 2025)
Radiopharmaceuticals Market Challenges to Growth
Fragile Isotope Supply — Roughly 95% of the world's Mo-99 comes from six reactors, five of them over 50 years old, and the October 2024 Petten outage cut U.S. Tc-99m supply by up to 40%.
Pricing Pressure and Generic Entry — Pylarify's 2025 revenue slipped 6.5% to USD 989.1 Mn as rival PSMA tracers arrived, and Curium's Bexlutry brings generic competition to Lutetium-177 therapy.
Despite these challenges, the market is set to climb from USD 9,248.6 Mn in 2025 to USD 25,884.6 Mn by 2035.
What Industry Leaders Are Saying About the Radiopharmaceuticals Market
The earlier indication for Pluvicto could really change our treatment paradigms for patients with mCRPC.
(Source: Novartis media release, March 2025)
With the new approval, the need for doses may increase up to sixfold compared to 2024 estimates.
(Source: Applied Radiology, June 2025)
A few weeks of reduced technetium supply is acceptable for some conditions, but this can't drag on.
(Source: Health Imaging, November 2024)
Patient flow for radioligand therapy remains complex and time-consuming, with long waits between disease progression and treatment slots. (paraphrased)
(Source: UroToday coverage of ESMO 2025, October 2025)
Report Segmentation & Scope
| Vectomat Insights | Market & Reports — Report Segmentation & Scope | |
|---|---|
| Scope Included in the Study | |
| By Product Type |
|
| By Isotope Type |
|
| By Application |
|
| By End User |
|
| Regional Analysis | |
| North America | The U.S., Canada, Mexico |
| Europe | Germany, France, U.K., Italy, Spain, Russia, BENELUX, Sweden, Denmark, Poland, Austria, Rest of Europe |
| Asia Pacific | China, Japan, India, South Korea, Australia, Thailand, Indonesia, Vietnam, Malaysia, Philippines, Taiwan, Rest of Asia Pacific |
| Latin America | Brazil, Argentina, Colombia, Chile, Peru, Rest of Latin America |
| The Middle East | GCC (Saudi Arabia, UAE, Qatar, Kuwait, Bahrain, Oman), Israel, Turkey, Iran, Rest of Middle East |
| Africa | South Africa, Egypt, Nigeria, Algeria, Morocco, Rest of Africa |
| Note: The scope can be further tailored as per your specific requirement. Contact sales@vectomatinsights.com | |
Who Are the Leading Companies in the Radiopharmaceuticals Market?
Key players operating in the Global Radiopharmaceuticals market include Novartis (Switzerland), Lantheus (U.S.), Curium (U.S.), GE HealthCare (U.S.), Bayer (Germany), Telix Pharmaceuticals (Australia), Cardinal Health (U.S.), Eckert & Ziegler (Germany), ITM Isotope Technologies Munich (Germany), NorthStar Medical Radioisotopes (U.S.), Bristol Myers Squibb (U.S.), Siemens Healthineers (Germany), SHINE Technologies (U.S.), Jubilant Pharmova (India), and SK Biopharmaceuticals (South Korea), among others. The field is consolidating fast. Curium's planned purchase of Lantheus would put PSMA-PET leadership and generic radioligands under one owner, and GE HealthCare is buying PET manufacturing scale through Sofie. Isotope suppliers have become kingmakers, which is why therapy developers are signing multi-year Actinium-225 contracts before their own drugs are approved.
Recent Developments in the Radiopharmaceuticals Market
July 2026 — Novartis: FDA approved Pluvicto in combination with an androgen-receptor pathway inhibitor for PSMA-positive metastatic hormone-sensitive prostate cancer, based on the 1,144-patient PSMAddition trial.
August 2026 — Curium: Curium agreed to acquire Lantheus for up to USD 8.0 Bn (up to USD 114.50 per share including a USD 12.00 CVR), with closing expected in the first half of 2027.
August 2026 — Bristol Myers Squibb: Announced a USD 173 Mn, 225,000-square-foot second RayzeBio radiopharmaceutical manufacturing plant in Whitestown, Indiana.
August 2026 — ITM Isotope Technologies Munich: FDA issued a Complete Response Letter for ITM-11 (Lu-177 edotreotide) in neuroendocrine tumours, citing CMC and third-party facility issues rather than efficacy or safety.
September 2026 — Curium: FDA approved Bexlutry (Lu-177 dotatate), the first radioligand equivalent to Novartis' Lutathera, via the 505(b)(2) pathway.
October 2026 — GE HealthCare: Agreed to acquire Sofie Biosciences for USD 945 Mn, adding 15 U.S. manufacturing sites, 21 cyclotrons and the Phase 3 FAPI-74 PET agent; closing expected in the first half of 2027.
Frequently Asked Questions
What is the Radiopharmaceuticals market size and forecast?
The Global Radiopharmaceuticals market was valued at USD 9,248.6 Mn in 2025 and is forecast to reach USD 25,884.6 Mn by 2035, a 10.84% CAGR over 2026–2035. Growth comes from both sides of the category: diagnostic tracers still hold 57.0% of revenue, while therapeutic agents such as Lutetium-177 radioligands grew at a 15.3% two-year CAGR to 2025. The full forecast is broken down by product, isotope, application, end user and region, according to Vectomat Insights.
Which region dominates the Radiopharmaceuticals market?
North America dominates with a 40.3% share of 2025 revenue, worth USD 3,727.2 Mn, and the U.S. alone accounts for USD 2,929.2 Mn. Its lead rests on CMS separate payment for diagnostic radiopharmaceuticals, a dense radiopharmacy network and nearly 600 sites able to deliver Pluvicto. Asia Pacific is the fastest-growing region, with South Korea expanding at a 13.0% CAGR and Japan at 11.1% through 2035, according to Vectomat Insights.
What are the key growth drivers of the Radiopharmaceuticals market?
Three drivers stand out. Radioligand therapy labels keep widening, most recently with Pluvicto's July 2026 approval in hormone-sensitive prostate cancer. U.S. reimbursement now pays separately for diagnostic radiopharmaceuticals above USD 630 per day, which helped launches such as Gozellix and Flyrcado. And manufacturers are adding isotope capacity, including Bristol Myers Squibb's USD 173 Mn Indiana plant and Cardinal Health's fourfold rise in Actinium-225 output, according to Vectomat Insights.
Who are the leading companies in the Radiopharmaceuticals market?
Leading companies include Novartis, Lantheus, Curium, GE HealthCare, Bayer, Telix Pharmaceuticals, Cardinal Health, Eckert & Ziegler, ITM Isotope Technologies Munich, NorthStar Medical Radioisotopes, Bristol Myers Squibb, Siemens Healthineers, SHINE Technologies, Jubilant Pharmova and SK Biopharmaceuticals. The field is consolidating: Curium agreed to acquire Lantheus for up to USD 8.0 Bn in August 2026, and GE HealthCare agreed to buy Sofie Biosciences for USD 945 Mn in October 2026, according to Vectomat Insights.
How is the Radiopharmaceuticals market segmented?
The report segments the market by product type (diagnostic and therapeutic), by isotope type (Technetium-99m, Iodine-131, Lutetium-177, Gallium-68, Fluorine-18, Actinium-225, Yttrium-90 and Radium-223), by application (oncology, cardiology, neurology, thyroid disorders and others) and by end user (hospitals, diagnostic imaging centers, academic and research institutes, and cancer treatment centers), across six regions. Diagnostic agents lead with 57.0% share, according to Vectomat Insights.
How can I access the full VMI Radiopharmaceuticals market report?
You can request a free sample or buy the full Radiopharmaceuticals Market Report on the Vectomat Insights website, or email sales@vectomatinsights.com. The report runs to 300+ pages with 96 tables and 70 figures, and covers 35+ countries, 15 company profiles and a ten-year forecast to 2035. Customization of up to 10% of scope is included at no extra cost, according to Vectomat Insights.
Access the Complete Radiopharmaceuticals Market Report
300+ pages | Global coverage | PDF | 2026
Contact: sales@vectomatinsights.com
About Vectomat Insights
Vectomat Insights is a leading market research company. We create authoritative, data-forward reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organisations but also with the newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is updated constantly in order to fulfil our clients' requirements for prompt and direct online access. Keeping in mind the client's needs, we have included expert insights on global industries, products, and market trends in this database.
Contact: Vectomat Insights | Email: sales@vectomatinsights.com | Website: www.vectomatinsights.com · +1 416-876-0312